Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




Brain Protein May Help Assess Recovery Time Following Concussion

By LabMedica International staff writers
Posted on 17 Jan 2017
An initial study of blood samples from athletes has indicated that elevated levels of the brain protein tau following a sport-related concussion are associated with a longer recovery period and delayed return-to-play (RTP), suggesting that tau may serve as a marker to help physicians determine an athlete’s recovery status and RTP readiness.

Despite the 3.8 million sports-related concussions that occur annually in the United States, there are no objective tools to confirm when an athlete is ready to resume play. Returning to play too early, before the brain has healed, increases an athlete’s risk of long-term physical and cognitive problems, especially if he or she sustains another concussion. Currently, physicians and trainers must make RTP decisions based on an athlete’s subjective, self-reported symptoms and their performance on standardized tests of memory and attention.

A research team led by Jessica Gill, RN, PhD of National Institute of Nursing Research (NINR) at National Institutes of Health (NIH) and Jeffrey Bazarian, MD, MPH, of University of Rochester Medical Center evaluated changes in tau in 46 Division I and III college athletes who experienced a concussion. Tau (which plays a role in the development of chronic traumatic encephalopathy (CTE), frontotemporal dementia, and Alzheimer’s disease) was measured by immunoassay of preseason blood plasma samples and again within 6 hours following concussion. The assay employed an ultra-sensitive digital-array technology that uses a single molecule enzyme-linked immunoarray (Simoa, by Quanterix), enabling detection of single protein molecules.

The athletes – a mix of soccer, football, basketball, hockey and lacrosse players from the University of Rochester and Rochester Institute of Technology – were divided into 2 groups based on recovery time. Athletes in the “long RTP” group took more than 10 days to RTP following concussion, while athletes in the “short RTP” group took less than 10 days to return to their sport.

Individuals in the long RTP group had higher levels of tau in their blood 6 hours after concussion compared to those in the short RTP group. Long RTP athletes also exhibited a jump in tau from preseason levels compared to their short RTP counterparts. Statistical analyses showed that higher blood tau concentrations 6 hours post-concussion consistently predicted that an athlete would take more than 10 days to resume play.

“This study suggests that tau may be a useful biomarker for identifying athletes who may take longer to recover after a concussion,” said Prof. Bazarian, “Athletes are typically eager to get back to play as soon as possible and may tell doctors that they’re better even when they’re not. Tau is an unbiased measurement that can’t be gamed, athletes can’t fake it. It may be that tau combined with current clinical assessments could help us make more informed RTP decisions and prevent players from going back to a contact sport when their brains are still healing.”

The study included both male and female athletes and showed that tau-related changes occurred in both genders across a variety of sports. The team found significant differences based on sex: women made up 61% of the long RTP group, but only 28% of the short RTP group. Prof. Bazarian said this isn’t surprising – it is well established that females take longer to recover following concussion than males.

The researchers acknowledge that the study is limited by its small size and that more research is needed to determine if tau can be established as a biomarker of concussion severity and/or recovery. Next steps include getting blood samples from athletes immediately following a concussion to see if the relationship between tau and RTP observed in the study holds true also on the sideline in the first few minutes following a head hit.

The study, by Gill J et al, was published in the January 6, 2017, issue of the journal Neurology.


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.